JENNIFER WARGO to Mohs Surgery
This is a "connection" page, showing publications JENNIFER WARGO has written about Mohs Surgery.
Connection Strength
0.217
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.140
-
Surgical management of melanoma. Hematol Oncol Clin North Am. 2009 Jun; 23(3):565-81, x.
Score: 0.077